TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03152838

Intervention type: GENETIC
Intervention: DNA methylation and Real-time Polymerase Chain Reaction Analysis
Description: Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes.

Intervention type: GENETIC
Intervention: DNA methylation and Real-time Polymerase Chain Reaction Analysis
Description: Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes.
Study: NCT01448135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite 1.2
Description: High protein enteral formula
Study: NCT00841256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergens in a water/glycerol solution
Description: In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
Study: NCT03152838

Intervention type: DIAGNOSTIC_TEST
Intervention: Gilliam Autism Rating Scale Arabic version
Description: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt.
Study: NCT00235014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril/verapamil
Description: 180/2 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil
Description: SR 240 mg QD
Study: NCT05264064

Intervention type: OTHER
Intervention: The motor assessment to establish validation of the Polish version of the AIMS
Description: The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
Study: NCT04369664

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
Study: NCT03365635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description
Study: NCT04369664

Intervention type: DRUG
Group type: OTHER
Intervention: PCSK9 inhibitor
Description: Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
Study: NCT04369664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered intravenously in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered intravenously in accordance with product labeling and local standards.
Study: NCT04369664

Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe 10mg
Description: Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
Study: NCT03424005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.
Study: NCT03809650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Description: macitentan 10 mg, film-coated tablet, oral use
Study: NCT02475005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain self management app on smartphone
Study: NCT03540615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1830839
Description: Dose escalation in healthy male subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01912183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication through PHR outside clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring device in PHR
Study: NCT03424005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.
Study: NCT01912183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity and sleep monitor
Study: NCT03365635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description
Study: NCT01246349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (Treatment Group)
Description: Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training (Control Group)
Description: Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
Study: NCT03424005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.
Study: NCT01912183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and sleep monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHR
Description: Access to their PHR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHR
Description: Access to their PHR
Study: NCT02510222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate
Description: Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02552810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steam clean
Description: Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma of Argon
Description: Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
Study: NCT00644176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin immediate release (Zithromax)
Description: azithromycin IR 500 mg tablet by mouth for 1 dose
Study: NCT00644176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: 2.0 g by mouth in the form of liquid for 1 dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT01949012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Capnography waveform and capnometry readings
Study: NCT01216956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid versus placebo
Description: Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extended-release nicotinic acid versus placebo
Description: Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
Study: NCT02913014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No AAD post Ablation.
Description: Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
Study: NCT00003407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study: NCT02348151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: The volunteers will perform the shuttle walk test on the treadmill

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corridor
Description: The volunteers will perform the shuttle walk test on the corridor
Study: NCT00981669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine
Description: 3 doses with 6 weeks interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 doses with 6 weeks interval
Study: NCT00811330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Description: Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
Study: NCT03554174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.1 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.1 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose Psilocybin
Description: 0.3 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose Psilocybin
Description: 0.3 mg/kg psilocybin capsule
Study: NCT01535508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid Vitamin D
Description: 300 IU/Kg/day not to exceed 10,000 IU/day.
Study: NCT04694365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: A single oral dose of 50 mg Fluzoparib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: A single oral dose of 50 mg Fluzoparib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: A single oral dose of 50 mg Fluzoparib will be administered.
Study: NCT01877967

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
Study: NCT03424005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib (dose #2)
Description: Inavolisib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT01877967

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03424005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (dose #2)
Description: Ribociclib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (dose #2)
Description: Ribociclib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib (dose #1)
Description: Inavolisib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT01442311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced DOT (both pegylated interferon alfa-2a and ribavirin)
Description: Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard DOT (PEG-DOT control arm)
Description: Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
Study: NCT04614922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.